A model-based analysis of a 28-week randomized meal-test substudy comparing tirzepatide 15 mg with semaglutide 1 mg in metformin-treated type 2 diabetes. PICO summary and expert commentary.
Browsing: Tirzepatide
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg)…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40…
A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.
In adults with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight compared to placebo, with notable improvements in sleep-related outcomes and cardiovascular risk factors, albeit with increased gastrointestinal side effects.